Patent ID: 11873511
Assignee: CELLECTIS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. A population of engineered primary human NK or T cells, comprising an exogenous coding sequence encoding an interleukin selected from IL-15, IL-12, or IL-2 inserted into an endogenous gene such that said interleukin is under transcriptional control of an endogenous gene promoter locus, while disrupting the coding sequence of the endogenous gene,
wherein the endogenous gene encodes PD1;
wherein said primary human NK or T cells further comprise an exogenous coding sequence encoding a chimeric antigen receptor (CAR) or a recombinant TCR; and
wherein said primary human NK or T cells secrete a level of the interleukin sufficient to enhance the antitumor activity of the cells.